Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ463MR)

This product GTTS-WQ463MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ463MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5534MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ4031MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ11699MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ12637MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ13353MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ4248MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ10619MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ15941MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW